Clinical DataThe atacicept Ph3 ORIGIN3 study in IgAN met its interim primary endpoint, supporting accelerated approval.
Financial PerformanceVera had cash and cash equivalents of approximately $557M, which is believed to be sufficient to fund operations in the foreseeable future.
Market PotentialAtacicept could reach blockbuster status with even a small share of the IgAN market, indicating significant upside for VERA shares.